Since ER+ breast cancer shows higher levels of K19 relative to other subtypes, and KRT19 KO cells exhibit decreased sensitivity to CDK inhibitors, decreased levels of K19 may underlie de novo resistance to CDK inhibition observed in clinic56. This evidence concerns the gene KRT19 and breast cancer.